We are currently developing our own vaccine against COVID-19, our vaccine is based on a Human cell line platform expressing structural glycoproteins with Immunogenic carrier VLPs. Virus-like particles (VLPs) are molecules closely resembling viruses, thus rendering an immunogenic response other viral vaccines are producing.

​

We have long experience of developing similar corona virus based on SARS vaccine within a short time period. We are fully confident our own new coronavirus vaccine will have the same SAFE approach.